The mechanism of its action in breast cells is the competition with endogenous estrogens for binding estrogen receptor α; thus, tamoxifen inhibits the estrogen-driven, pro-proliferative transcription program in breast cancer cells[6,7] and also activates G-protein-coupled ER (GPER1)[8]. Here, ESR1 is linked to breast carcinoma.